Mycobacterial immune reconstitution inflammatory syndrome in HIV-1 infection after antiretroviral therapy is associated with deregulated specific T-cell responses: Beneficial effect of IL-2 and GM-CSF immunotherapy

Table 1 Clinical features of IRIS patients

Patient	CD4 T cell count before ART cells/μl	CD4 T cell count at presentation of IRIS cells/μl	Fold change in CD4 T cell counts from baseline to IRIS presentation	CD4 T cell count after remission of IRIS cells/μl	HIV-1 RNA at presentation of IRIS copies/ml	Reason for admission	Time on therapy*	Therapy
1	7	69	9.86	202	U/D	MAC	8	d4T+ddI+NFV+ImRx
2	37	70	1.89	140	U/D	MAC	12	AZT+3TC+IDV+ImRx
3	4	45	11.25	93	U/D	MAC	18	d4T+ddI+NFV+ImRx
4	90	280	3.11	601	U/D	MAC	8	AZT+3TC+EFV+ImRx

*Time in months from initiation of potent ART until diagnosis of IRIS. Drugs used in ART regime: Nucleoside analogues; Stavudine (d4T), Didanosine (ddI), Lamivudine (3TC) and Zidovudine (AZT) Protease inhibitors; Nelfinavir (NFV), Indinavir (IDV), or Non-nucleoside reverse transcriptase inhibitor; Efavirenz (EFV); ImRx = immunotherapy; MAC = Mycobacterium avium complex.